11/20
11:12 am
cort
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet [Yahoo! Finance]
11/20
10:12 am
cort
Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
Medium
Report
Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
11/8
08:56 am
cort
5 Small Drug Stocks to Buy as Trump Gets Re-Elected [Yahoo! Finance]
Medium
Report
5 Small Drug Stocks to Buy as Trump Gets Re-Elected [Yahoo! Finance]
11/5
11:04 am
cort
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? [Yahoo! Finance]
Medium
Report
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? [Yahoo! Finance]
11/4
11:43 am
cort
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
11/4
11:43 am
cort
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade [Yahoo! Finance]
11/4
10:47 am
cort
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why [Yahoo! Finance]
Low
Report
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why [Yahoo! Finance]
11/1
02:04 pm
cort
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? [Yahoo! Finance]
Low
Report
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? [Yahoo! Finance]
11/1
08:40 am
cort
Corcept's relacorilant GRADIENT trial misses primary endpoint [Yahoo! Finance]
Low
Report
Corcept's relacorilant GRADIENT trial misses primary endpoint [Yahoo! Finance]
11/1
08:17 am
cort
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
10/31
11:05 pm
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Medium
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
10/31
08:35 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
High
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
10/30
04:05 pm
cort
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
Low
Report
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
10/23
04:05 pm
cort
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Low
Report
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
10/18
03:33 pm
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Sandler O'Neill.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Sandler O'Neill.
10/18
08:33 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $45.00 to $80.00. They now have a "buy" rating on the stock.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $45.00 to $80.00. They now have a "buy" rating on the stock.
10/17
11:31 am
cort
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High? [Yahoo! Finance]
10/17
10:32 am
cort
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
Low
Report
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
10/15
09:46 am
cort
Corcept: Key Announcements Coming Soon [Seeking Alpha]
Low
Report
Corcept: Key Announcements Coming Soon [Seeking Alpha]
10/8
03:53 pm
cort
3 US Growth Stocks With Insider Ownership And 20% Revenue Growth [Yahoo! Finance]
Low
Report
3 US Growth Stocks With Insider Ownership And 20% Revenue Growth [Yahoo! Finance]
10/7
08:01 am
cort
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals? [Yahoo! Finance]
Low
Report
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals? [Yahoo! Finance]
9/30
03:17 pm
cort
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast [Yahoo! Finance]
Low
Report
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast [Yahoo! Finance]
9/30
10:58 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $65.00 to $76.00. They now have a "buy" rating on the stock.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $65.00 to $76.00. They now have a "buy" rating on the stock.
9/25
07:54 am
cort
Does Corcept Therapeutics (CORT) Have a Long Runway for Growth? [Yahoo! Finance]
Medium
Report
Does Corcept Therapeutics (CORT) Have a Long Runway for Growth? [Yahoo! Finance]
9/18
02:07 pm
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $38.00 to $67.00. They now have an "overweight" rating on the stock.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $38.00 to $67.00. They now have an "overweight" rating on the stock.